 Abstract pharmaceuticals selected for exploration space missions must remain stable and effective throughout mission timeframes. Although there have been six spaceflight drug stability studies, there has not been a comprehensive analytical analysis of these data. To address this gap, we sought to use these studies to quantify the rate of spaceflight drug degradation and the time-dependent probability of drug failure resulting from the loss of active pharmaceutical ingredient, API. Additionally, existing spaceflight drug stability studies were reviewed to identify research gaps to be addressed prior to exploration missions. Data were extracted from the six spaceflight studies to quantify API loss for 36 drug products with long-duration exposure to spaceflight. Medications stored for up to 2.4 years in low Earth orbit, Elio, exhibited a small increase in the rate of API loss with a corresponding increase in risk of product failure. Overall, the potency for all spaceflight exposed medications remained within 10% of terrestrial lot-matched control with a 1.5 increase in degradation rate. Nonprotective repackaging was found to be the most. This article was authored by J. F. Richard, S. E. Phelps, K. R. Lenhart, and others. We are article.tv, links in the description below.